Neuroendocrine Tumor

Our findings indicate that DLL3 is frequently expressed in MTC and its high expression identifies tumors with aggressive pathological characteristics and poor clinical outcomes. These results support DLL3 as a potential prognostic biomarker and therapeutic target in MTC, highlighting the need for further validation and integration into clinical trials of DLL3-directed therapies.

By harmonizing biological and morphological information, RECIN provides a practical and reproducible framework tailored to the indolent, receptor-driven biology of NETs. Prospective multicenter validation, and correlation with longer term outcomes are needed to establish RECIN as standardized response criteria for PRRT as well as other treatment modalities for well-differentiated NETs.

This tumor-specific differentiation-driven model has significant implications for patient management, treatment planning, and prognosis. Understanding these tumor-specific differentiation patterns allows clinicians to optimize diagnostic imaging and therapeutic strategies in precision oncology and personalized medicine.

Although radioiodine provides the historical foundations of theranostics, the prototype RLTs include 68Ga-DOTATATE and 177Lu-DOTATATE, which target somatostatin receptor subtype 2 in neuroendocrine tumors, and 68Ga-PSMA-617 and 177Lu-PSMA-617, which target prostate cancer. RLT, weaponized in cancer management through advances in instrumentation and radiochemistry, is transforming the nuclear oncology landscape. Equitable access to these advanced tools remains a global consideration.

P4, N=400, Recruiting, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Overall, the lineage-aligned synthesis indicates that NF-PitNETs progress through diverse molecular pathways, with each subtype dominated by distinct regulatory networks. Although many biomarkers show promise, most remain exploratory, highlighting the need for harmonised methods and multicentre validation to support precision diagnostics and prognostic modelling.

Clinically approved agents, such as 177Lu-DOTATATE and 177Lu-PSMA-617, are used for neuroendocrine tumors and metastatic castration-resistant prostate cancer, respectively, with significant therapeutic efficacy. The potential avenues include theranostics, predictive modeling for patient selection, and new molecular targeting strategies. This review highlights the transformative potential of RPhs in precision oncology, providing an overview of the current clinical applications and future research trajectories toward improved cancer management.

P1/2, N=150, Recruiting, Crinetics Pharmaceuticals Inc. | Not yet recruiting --> Recruiting

This case study highlights that the presence of pNETs should be considered in patients with MEN-1 and multiple abnormal hormone levels. Timely surgical management of the involved glands and postoperative complications can effectively improve prognosis.

P=N/A, N=680, Recruiting, Fudan University | N=440 --> 680

TACE-STZ provided a higher ORR than TAE, although yielded longer PFS only in patients with panNET. Low tumor expression of APNG might help select the best candidates for TACE-STZ, although this result was only exploratory.

The predominant presentation with non-specific abdominal pain significantly amplifies diagnostic complexity in such cases. This underscores the necessity for heightened clinical vigilance for NENs when evaluating atypical presentations.